Cite
MLA Citation
B Xu et al.. “LBA6First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098040444.0x000037